TORONTO, June 28, 2013 /CNW/ - Dr. Calvin R. Stiller, Chair of the Board
of Directors of the Ontario Institute for Cancer Research (OICR), today
congratulated Dr. Thomas J. Hudson, OICR's President and Scientific
Director, on behalf of the Board, on his appointment as an Officer of
the Order of Canada.
"Tom Hudson has distinguished himself at every stage in his career and
even more so since taking the leadership of OICR," said Dr. Stiller.
"The international reputation of the science and the significant
accomplishments that have resulted from his vision and execution are
recognized in this honour and the Board of Directors is proud to have
him as President of the Institute."
"Ontario has been able to attract and retain some of the brightest
cancer researchers with Dr. Hudson's innovative leadership," said Reza
Moridi, Ontario's Minister of Research and Innovation. "He has enhanced
Ontario's position as a leading jurisdiction in cancer research and we
applaud the honour bestowed on him today."
OICR was launched in 2005 to tackle the big issues in cancer. It focuses
on translational research in prevention, detection, diagnosis and
treatment. Dr. Hudson's appointment to the Order of Canada was made in
recognition of his international leadership in genomics and human
genome variation. He was the Founder and Director of the McGill
University and Genome Quebec Innovation Centre and Assistant-Director
of the Whitehead/MIT Center for Genome Research, where he led a team
that generated physical and gene maps of the human and mouse genomes.
Dr. Hudson was a founding member of the International Haplotype Map
Consortium and the Public Population Project in Genomics (P3G).
In addition to being instrumental in the creation of the International
Cancer Genome Consortium (ICGC), he now serves as Chair of both its
Executive Committee and International Scientific Steering Committee.
The ICGC was created to coordinate research projects whose goal is to
unravel the genomic changes in cancer. The knowledge generated by the
ICGC projects will lead to personalized cancer treatments. There are
currently 55 project teams in 15 jurisdictions in Asia, Australia,
Europe, North America and South America studying more than 25,000
Dr. Hudson is a member of the Steering Committee of the Global Alliance
to Enable the Responsible Sharing of Genomic and Clinical Data, which
was launched in June 2013, and is a co-author of the White Paper
produced by the Alliance which details the purpose and benefits of
establishing an international framework to allow genetic and clinical
data to be collected, managed and shared in an effective, responsible,
In 2007, Dr. Hudson was appointed Professor in the Departments of
Molecular Genetics and Medical Biophysics at the University of Toronto
and he is a fellow of the Royal Society of Canada. He is
editor-in-chief of the journal Human Genetics and has co-authored more
than 250 peer-reviewed scientific publications.
SOURCE: Ontario Institute for Cancer Research
For further information:
Director of Communications